Efficacy of ICE plus Bevacizumab Therapy for Temozolomide-Resistant Anaplastic Astroblastoma: Case Report

被引：0

作者：

Saito, Kiyotaka ^{[1
]}

Yamashita, Shinji ^{[1
]}

Kawano, Tomoki ^{[1
]}

Yokoyama, Takahiro ^{[1
]}

Fukushima, Tsuyoshi ^{[2
]}

Yokogami, Kiyotaka ^{[1
]}

Takeshima, Hideo ^{[1
]}

机构：

[1] Univ Miyazaki, Fac Med, Div Clin Neurosci, Dept Neurosurg, Miyazaki, Japan

[2] Univ Miyazaki, Fac Med, Div Pathol, Dept Oncopathol & Regenerat Biol, Miyazaki, Japan

来源：

BRAIN PATHOLOGY | 2019年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P3-24

引用

页码：146 / 146

页数：1

共 50 条

[1] Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma
Guo, Gao
Gong, Ke
Puliyappadamba, Vineshkumar Thidil
Panchani, Nishah
Pan, Edward
Mukherjee, Bipasha
Damanwalla, Ziba
Bharia, Sabrina
Hatanpaa, Kimmo J.
Gerber, David E.
Mickey, Bruce E.
Patel, Toral R.
Sarkaria, Jann N.
Zhao, Dawen
Burma, Sandeep
Habib, Amyn A.
NEURO-ONCOLOGY, 2019, 21 (12) : 1529 - 1539
[2] Bevacizumab/temozolomide/vemurafenibLack of efficacy: case report
Reactions Weekly, 2023, 1952 (1) : 106 - 106
[3] A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma
Jiayi Huang
Rekha Chaudhary
Adam L. Cohen
Karen Fink
Samuel Goldlust
John Boockvar
Prakash Chinnaiyan
Leping Wan
Stephen Marcus
Jian L. Campian
Journal of Neuro-Oncology, 2019, 142 : 537 - 544
[4] A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma
Huang, Jiayi
Chaudhary, Rekha
Cohen, Adam L.
Fink, Karen
Goldlust, Samuel
Boockvar, John
Chinnaiyan, Prakash
Wan, Leping
Marcus, Stephen
Campian, Jian L.
JOURNAL OF NEURO-ONCOLOGY, 2019, 142 (03) : 537 - 544
[5] Efficacy of temozolomide and bevacizumab for the treatment of leptomeningeal dissemination of recurrent glioblastoma: A case report
Okita, Yoshiko
Nonaka, Masahiro
Umehara, Toru
Kanemura, Yonehiro
Kodama, Yoshinori
Mano, Masayuki
Nakajima, Shin
ONCOLOGY LETTERS, 2015, 9 (04) : 1885 - 1888
[6] Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma
Quinn, Jennifer A.
Jiang, Sara Xiaoyin
Reardon, David A.
Desjardins, Annick
Vredenburgh, James J.
Rich, Jeremy N.
Gururangan, Sridharan
Friedman, Allan H.
Bigner, Darell D.
Sampson, John H.
McLendon, Roger E.
Herndon, James E., II
Walker, Amy
Friedman, Henry S.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) : 1262 - 1267
[7] Reducing Chemo-/Radioresistance to Boost the Therapeutic Efficacy against Temozolomide-Resistant Glioblastoma
Yun, Baofeng
Gu, Zhengpeng
Liu, Zheng
Han, Yaobao
Sun, Qiao
Li, Zhen
ACS APPLIED MATERIALS & INTERFACES, 2022, 14 (34) : 38617 - 38630
[8] The efficacy of stereotactic radiotherapy followed by bevacizumab and temozolomide in the treatment of recurrent glioblastoma: a case report
Zhong, Wangyan
Mao, Jiwei
Wu, Dongping
Peng, Jianghua
Ye, Wanli
FRONTIERS IN PHARMACOLOGY, 2024, 15
[9] Metformin plus sorafenib highly impacts temozolomide-resistant glioblastoma stem-like cells
Aldea, Mihaela D.
Petrushev, Bobe
Soritau, Olga
Tomuleasa, Ciprian I.
Berindan-Neagoe, Ioana
Filip, Adriana G.
Chereches, Gabriela
Cenariu, Mihai
Craciun, Lucian
Tatomir, Corina
Florian, Ioan-Stefan
Crivii, Carmen B.
Kacso, Gabriel
JOURNAL OF BUON, 2014, 19 (02): : 502 - 511
[10] Safety and efficacy of the addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma multiforme
Vredenburgh, James J.
Desjardins, Annick
Peters, Katherine B.
Reardon, David A.
Herndon, James Emmett
Coan, April D.
Kirkpatrick, John
Bailey, Leighann
Threatt, Stevie
Sampson, John Howard
Friedman, Allan H.
Friedman, Henry S.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →